Editorials

Long-Term Safety of Tolvaptan in ADPKD

Where Do We Stand?

Dipal M. Patel and Neera K. Dahl
CJASN January 2021, 16 (1) 3-5; DOI: https://doi.org/10.2215/CJN.17981120

Article Information

vol. 16 no. 1 3-5
DOI 
https://doi.org/10.2215/CJN.17981120
PubMed 
33376103
Published By 
American Society of Nephrology
Print ISSN 
1555-9041
Online ISSN 
1555-905X
History 
  • Published online January 7, 2021.

Article Versions

Copyright & Usage 
Copyright © 2021 by the American Society of Nephrology

Author Information

  1. Dipal M. Patel, and
  2. Neera K. Dahl
  1. Section of Nephrology, Department of Internal Medicine, Yale University, New Haven, Connecticut
  1. Correspondence:
    Dr. Neera K. Dahl, Nephrology, Yale University School of Medicine, 330 Cedar Street, BB 114, New Haven, CT 06510. Email: neera.dahl{at}yale.edu

Statistics from Altmetric.com

Article usage

Article usage: December 2020 to February 2021

AbstractFullPdf
Dec 202009332
Jan 20210550356
Feb 202109368
Back to top

In this issue

View Selected Citations (0)
Print
Download PDF
Email Article
Citation Tools
Request Permissions
Long-Term Safety of Tolvaptan in ADPKD
Dipal M. Patel, Neera K. Dahl
CJASN Jan 2021, 16 (1) 3-5; DOI: 10.2215/CJN.17981120
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Keywords